Emphasizing the benefits of annual lung cancer screening with low-dose computed tomography (CT), researchers noted high 20-year survival rates for a variety of early-stage lung cancer tumor presentations, including a 100 percent survival rate for those with non-solid or partly solid cancerous nodules.
A recent report from the American Lung Association indicated that only 5.8 percent of Americans eligible for lung cancer screening follow through with the preventative, life-saving measure.1
However, detection of early-stage lung cancer via low-dose computed tomography (CT) may lead to a 20-year survival rate of 80 percent, according to the findings of a large international study being presented next week at the Radiological Society of North America (RSNA) annual conference in Chicago.2
In the study of 1,285 people with early-stage lung cancer diagnosed on CT scans, researchers noted a 100 percent 20-year survival rate for 139 study participants with non-solid lung nodules, and 155 patients with partly solid nodules. The study authors also pointed to a 73 percent 20-year survival rate in 991 people who had solid nodule presentations.2
“What we present here is the 20-year follow-up on participants in our screening program that were diagnosed with lung cancer and subsequently treated,” noted lead study author Claudia Henschke, Ph.D., M.D., a professor of radiology and director of the Early Lung and Cardiac Action Program at the Icahn School of Medicine at Mount Sinai in New York. “The key finding is that even after this long-time interval, they are not dying of their lung cancer.”
Henschke and colleagues also noted an 86 percent survival rate for people diagnosed with stage 1A lung cancers and a 92 percent survival rate for study participants who underwent resection of pathologic stage 1A tumors that were 10 cm or less in average diameter and width.2
“While screening doesn’t prevent cancers from occurring, it is an important tool in identifying lung cancers in their early stage when they can be surgically removed,” said Dr. Henschke.
All of the study participants were enrolled in the International Early Lung Cancer Action Program (I-ELCAP), a multinational program that emphasizes advance CT lung cancer screening and has enrolled over 87,000 people since 1992.
References
1. American Lung Association. New report: Critically low lung cancer screening rates reveal opportunity to save more lives. Available at: https://www.lung.org/media/press-releases/state-of-lung-cancer-2022 . Published November 15, 2022. Accessed November 21, 2022.
2. Radiological Society of North America (RSNA). Lung cancer screening dramatically increases long-term survival rate. Cision. PR Newswire. Available at: www.prnewswire.com/news-releases/lung-cancer-screening-dramatically-increases-long-term-survival-rate-301681836.html . Published November 22, 2022. Accessed November 22, 2022.
Study with CT Data Suggests Women with PE Have More Than Triple the One-Year Mortality Rate than Men
April 3rd 2025After a multivariable assessment including age and comorbidities, women with pulmonary embolism (PE) had a 48 percent higher risk of one-year mortality than men with PE, according to a new study involving over 33,000 patients.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
New AI-Enabled Portable Ultrasound May Facilitate 50 Percent Reduction in Cardiac Imaging Scan Time
March 28th 2025Artificial intelligence (AI)-powered measurement capabilities provide key features with the Compact Ultrasound 5500CV device, which was unveiled at the American College of Cardiology (ACC) conference.
GE HealthCare Launches PET MPI Agent Flyrcado at ACC Conference
March 28th 2025The positron emission tomography myocardial perfusion imaging (PET MPI) agent, which offers a significantly higher half-life than other cardiac PET agents, was recently granted pass-through payment status by CMS that will go into effect on April 1, 2025.